The World Health Organization has prequalified another novel oral polio vaccine type 2 (nOPV2), a move that is expected to accelerate global eradication efforts. Prequalification is an international quality and safety certification that allows United Nations agencies, including UNICEF, to procure and distribute the vaccine for immunisation campaigns. The development comes at a time when polio remains endemic in limited areas, even though it has been eliminated from many parts of the world.
What the Prequalification Means
Prequalification confirms that a vaccine meets global standards for safety, quality and effectiveness. It is a key step in large-scale public health programmes. Once prequalified, the vaccine can be purchased by international agencies and used in mass vaccination drives in countries facing polio transmission.
Why nOPV2 Matters
The novel oral polio vaccine type 2 is designed to be more genetically stable than older oral polio vaccines. This reduces the risk that the vaccine itself could mutate and trigger outbreaks. At the same time, it remains effective in stopping person-to-person transmission of poliovirus, which is essential in outbreak response settings.
Global Polio Eradication Efforts
Polio is a disabling and potentially life-threatening disease that mainly affects children. Global eradication efforts have already removed the disease from most regions, but transmission continues in a few countries. Recent international commitments, including funding support for eradication campaigns, aim to protect hundreds of millions of children each year through immunisation and surveillance.
Public Health Significance
The prequalification of nOPV2 strengthens the global vaccine toolkit against polio. It supports faster outbreak response, wider vaccine access and safer immunisation strategies. The decision is also important for maintaining momentum towards the long-term goal of complete polio eradication.
Last Modified: April 28, 2026